Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX stock opened at $0.55 on Monday. The stock’s 50 day simple moving average is $0.72 and its 200 day simple moving average is $3.06. Eagle Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $6.81.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Mackenzie Financial Corp bought a new position in Eagle Pharmaceuticals during the 2nd quarter worth $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eagle Pharmaceuticals during the second quarter valued at $65,000. Fidelis Capital Partners LLC bought a new position in shares of Eagle Pharmaceuticals during the second quarter worth about $71,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth about $76,000. Finally, Creative Planning acquired a new position in Eagle Pharmaceuticals during the 3rd quarter valued at about $59,000. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.